Cluster headache is one of the most severe pains known to humans. This condition causes intense stabbing or burning pain in or around the eye. If you suffer from chronic cluster headache, you may be eligible to participate in a new clinical research study.

Cluster headache refers to the characteristic grouping of headaches. Headaches start suddenly and the pain is of a short duration (usually 30 to 45 minutes). Most sufferers get one to four headaches a day during a cluster period. In 80 percent of sufferers, cluster headaches are episodic. The cluster periods last several weeks or months, but then disappear for months leaving considerable amounts of pain-free intervals between periods.

For chronic cluster headache patients, the cluster headache periods are continuous. Treatment is also more difficult. Patients tend not to respond to conventional forms of cluster therapy.

Doctors across the country are currently accepting participants for the Pathway CH-2 Study. The study is evaluating the ATI™ Neurostimulation System—an investigational device designed to provide targeted cluster headache relief. The ATI™ System works in conjunction with the sphenopalatine ganglion (SPG)—a nerve bundle located behind the nose that is known to play a major role in severe headaches. For decades, doctors have focused on the SPG for a variety of pain relief procedures.

The ATI™ Neurostimulation System is designed to provide direct, local stimulation to the SPG to interrupt and block nerve signals that cause cluster attack pain. It is smaller than an almond and placed through a minimally-invasive oral procedure. Once placed, you can control your own stimulation as needed by turning on the remote controller and holding it to your cheek. To stop the stimulation, simply remove the controller from your cheek.

The National Headache Foundation is working to inform more potential participants about the Pathway CH-2 Study. To be eligible for the Pathway CH-2 Study, you must meet specific study criteria. These criteria have been designed to identify those individuals who are the most suitable candidates for the study. To see if you qualify, visit

Participants will be treated by a team of headache specialists and will receive study-related care at no cost.

There are currently doctors in Arizona, California, Connecticut, Florida, Illinois, Kentucky, Massachusetts, Michigan, Missouri, Nevada, New York, North Carolina, Pennsylvania, Texas, and Virginia enrolling patients for the Pathway CH-2 Study. Check out the map below for a clinical study site near you.

Caution: The ATI Neurostimulation System is an investigational device and is limited by United States law to investigational use.